Address
Amgen Inc
One Amgen Center Drive
Thousand Oaks, CA 91320
United States
Phone
Website
Recent investment activity
KANDO id: 116834
Corporate information
Official name
Amgen Incorporated
Registration country
Official identities
US CIK 0000318154
Affiliated entities
Funding rounds
| Investor | Profile | Country | |
|---|---|---|---|
|
Asset Management Co Venture Capital (Asset Management Ventures), (AMV) | Early-stage venture capital firm investing in digital health. | |
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Royalty Pharma AG | Acquisition of royalty interests in leading pharmaceutical and biotechnology products and holding them as part of a diversified portfolio |
Investment preferences
Actual initial investment stage
Investment activity status
Active investor
Selected investments
Displaying 1 - 10 of 10| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
|
|
Alantos Pharmaceuticals Holding Inc | Discoverer and developer of small molecule drugs for osteoarthritis/ inflammation and type II diabetes. | N/A | |||
|
|
Calistoga Pharmaceuticals Inc | Biopharmaceutical company dedicated to developing targeted therapies to improve the health of patients with cancer or inflammatory diseases. | N/A | |||
|
|
Theraclone Sciences Inc | Series B | ||||
|
|
Avidia Inc | Series B | ||||
|
|
Biovex Inc (Biovex Group Inc) | Biotechnology company developing new generation biologics for the treatment of cancer and infectious disease. | Acquisition | |||
|
|
Epizyme Inc | Focusing on the discovery and development of innovative drugs targeting epigenetic enzymes, in particular histone methyltransferases (HMTs). | Series B | |||
|
|
Miragen Therapeutics Inc | Ddeveloper of cardiovascular and muscle disease therapeutics based on microRNA biology. | Series B Initial investment | |||
|
Onyx Pharmaceuticals Inc | Acquisition Initial investment USD 10,500,000,000 (USD 10,500,000,000) | ||||
|
|
TetraLogic Pharmaceuticals | A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. | N/A | |||
|
VenBio Global Strategic Fund II LP | Fund Closing Initial investment |
Team
| Employee | Position | ||
|---|---|---|---|
| Robert Bradway | |||
| Kevin Sharer |